172 related articles for article (PubMed ID: 9020286)
21. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
22. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
23. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
24. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
Kameyama S; Yamazaki S; Kitamura T
Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
[TBL] [Abstract][Full Text] [Related]
25. [Hormonal treatment in prostate cancer].
Bastide C; Bruyère F; Karsenty G; Guy L; Rozet F
Prog Urol; 2013 Nov; 23(15):1246-57. PubMed ID: 24183083
[TBL] [Abstract][Full Text] [Related]
26. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation therapy for prostate cancer: current status and future prospects.
Miyamoto H; Messing EM; Chang C
Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
[TBL] [Abstract][Full Text] [Related]
28. Choice of first-line treatment for metastatic prostate cancer.
Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
[No Abstract] [Full Text] [Related]
29. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
30. Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Reis LO; Zani EL; García-Perdomo HA
Int Urol Nephrol; 2018 Jun; 50(6):993-1003. PubMed ID: 29600433
[TBL] [Abstract][Full Text] [Related]
31. Basis for hormonal management of advanced prostate cancer.
Geller J
Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
[TBL] [Abstract][Full Text] [Related]
32. Progress in the treatment of advanced prostate cancer.
Sternberg CN; Petrylak DP; Madan RA; Parker C
Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
[TBL] [Abstract][Full Text] [Related]
33. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
34. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
35. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
36. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
37. Maximal androgen blockade for advanced prostate cancer.
Schmitt B; Bennett C; Seidenfeld J; Samson D; Wilt T
Cochrane Database Syst Rev; 2000; 1999(2):CD001526. PubMed ID: 10796804
[TBL] [Abstract][Full Text] [Related]
38. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
39. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
40. Combined androgen blockade.
Crawford ED
Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
